Safety and Immunogenicity of Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to less than 18 Years of Age.

Trial Profile

Safety and Immunogenicity of Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to less than 18 Years of Age.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2015

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary) ; AS03B
  • Indications Influenza A virus H5N1 subtype
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 16 Jul 2015 According to ClinicalTrials.gov record treatment table, primary endpoints and secondary endpoints have been revised.
    • 03 Apr 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 12 Sep 2013 Planned end date changed from 1 Nov 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top